Senchyna Michelle, Wax Martin B
Alcon Research Ltd, 6201 South Freeway, Fort Worth, TX 76134-2009 USA.
J Ocul Biol Dis Infor. 2008 Mar;1(1):1-6. doi: 10.1007/s12177-008-9006-2. Epub 2008 Jul 16.
The successful development of a therapeutic agent targeting treatment of dry eye syndrome necessitates the demonstration of drug efficacy for both sign and symptom endpoints. As numerous therapeutic strategies incorporate a secretagogue function into their overall mechanism of action, the quantitative assessment of tear production serves as a logical endpoint to anchor "sign" efficacy. Although several methods including the Schirmer, the phenol red thread and tear clearance tests exist, their utility in clinical evaluations of novel therapeutics is unclear. The purpose of this review is to summarize findings and conclusions describing the performance of each of these tests so as to gain insight into which, if any, is most applicable for use in discovering new dry eye therapeutics.
开发一种针对干眼症治疗的治疗药物,必须证明其对体征和症状终点均具有药物疗效。由于众多治疗策略在其整体作用机制中纳入了促分泌功能,因此对泪液分泌进行定量评估便成为确定“体征”疗效的合理终点。尽管存在多种方法,包括Schirmer试验、酚红棉线试验和泪液清除试验,但其在新型治疗药物临床评估中的效用尚不清楚。本综述的目的是总结描述这些试验各自性能的研究结果和结论,以便深入了解哪一种(如果有的话)最适用于发现新的干眼症治疗药物。